Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lilly/Takeda (correction)

Executive Summary

Lilly said in April that Takeda would take over U.S. marketing for type 2 diabetes treatment Actos. The firm completed Actos detailing obligations in the U.S. at the end of Q1 but will continue to receive royalties on sales through the end of September, after which it will begin receiving a declining residual royalty. In a July 31 story, "The Pink Sheet" stated the Takeda agreement expired in April (1"The Pink Sheet" July 31, 2006, p. 4). Looking forward Lilly expects SG&A to grow at a lower rate than sales. The story reported the firm expected SG&A to grow at a higher rate than sales...

You may also be interested in...



Lilly Diabetes Sales Growth Slows; Newer Products Take The Lead

Despite efforts to strengthen its position in the diabetes market, revenue from Lilly's diabetes care franchise - Humulin, Humalog, Actos and Byetta - increased just 5% to $701.7 mil. in the second quarter, primarily on the strength of Byetta

Senators Bring Back Bill Mandating Medicare Payment For Breakthrough Technologies

Four US senators are leading a bipartisan effort to bring potentially life-saving medical treatments to Medicare beneficiaries by requiring reimbursement for breakthrough technologies cleared by the FDA. 

HHS/FDA Make It Official: Premarket Notification Required For 7 Types Of Class I Medical Gloves

A joint final order from the US Department of Health and Human Services and the Food and Drug Administration says makers of the low-risk gloves must have 510(k) clearance before sending their products to market.

UsernamePublicRestriction

Register

PS047452

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel